Invivyd reports positive Phase 1/2 results for VYD2311, showing safety, long half-life, and potential for effective COVID-19 prevention. Invivyd, Inc. announced promising results from its Phase 1/2 ...
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback